Insception Now Owns 100% of Lifebank

Insception Biosciences Inc. and Lifebank Corp. (TSX VENTURE:LBK) are pleased to
announce that Insception has acquired an additional 982,420 common shares in the
capital of Lifebank by way of compulsory acquisition following Insception's
previously announced offer to acquire all of the issued and outstanding common
shares of Lifebank. Insception now owns 11,313,361 common shares of Lifebank,
representing 100% of its issued and outstanding common shares.


Insception made its offer on August 20, 2012 when it mailed a take-over bid
circular to the shareholders of Lifebank. The deposit period under the offer
expired at 5:00 p.m. (Vancouver time) on September 25, 2012. Insception now
intends to apply to de-list the common shares of Lifebank from the TSX Venture
Exchange and to apply to securities regulatory authorities for Lifebank to cease
to be a reporting issuer.


"The acquisition of Lifebank by Insception is an industry first. It creates
Canada's only truly national family cord blood bank and brings service, quality
and stability to a new level for Canadian families", said Richard Lockie,
Inception's President and Chief Executive Officer. "Our commitment remains
unchanged; we will continue to be the vigilant stewards of cord blood stem cells
for Canadian families long-term." 


About Insception 

Insception is the largest cord blood program in Canada, with over 39,000 cord
blood units banked. Insception is a private company owned by Argosy Partners,
Mount Sinai Hospital, management and its scientific founders. By continuing to
partner with leading Canadian medical facilities such as Toronto's Mount Sinai
Hospital, the Insception Cord Blood Program is able to provide every Canadian
family with security, state of the art processing and storage, financial
stability and long term professional governance. For more information, visit
www.insception.com.


About Lifebank 

Started in 1996, Lifebank is a leading national company in the biomedical field
based at the British Columbia Institute of Technology campus in Burnaby.
Lifebank provides processing and cryogenic storage of umbilical cord blood stem
cells for families in Canada and worldwide. With proven quality systems,
Lifebank provides informed parents with the comfort that their children's cord
blood stem cells are processed and stored by an experienced, professional and
dedicated organization. Lifebank's website can be found at www.lifebank.com. 


Other Information 

Certain statements made herein are forward-looking statements that involve risks
and uncertainties. Often, but not always, forward looking statements can be
identified by the use of words such as "plans", "expects", "expected",
"scheduled", "estimates", "intends", "anticipates", or "believes", or variations
of such words and phrases, or state that certain actions, events or results
"may", "could", "would", "might" or "will" be taken, occur or be achieved. These
forward-looking statements reflect Insception's and Lifebank's best judgment
based on current information, factors and assumptions, and although the parties
base these statements on circumstances that the parties believe to be reasonable
when made, there can be no assurance that future events will not affect the
accuracy of such forward-looking information. As such, the forward-looking
statements are not guarantees of future performance or actions, and actual
performance and actions may vary materially from the actions and expectations
discussed in this press release. 


Each of Insception and Lifebank disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new information,
future events or otherwise, or to explain any material difference between
subsequent actual events and such forward-looking statements, except to the
extent required by applicable law.


This news release does not constitute an offer to buy or an invitation to sell,
or the solicitation of an offer to buy or invitation to sell, any of the
securities of Lifebank. Such an offer may only be made pursuant to an offer and
take-over bid circular filed with the securities regulatory authorities in
Canada.